IDH2 and glioblastoma: TMTC1 expression was also found to be potentially prognostic in recurrent GBM (IDH-wildtype) patients (p < 0.05; Log-rank test); however, sample sizes in comparative groups were below the minimum of ten required for a valid survival analysis.